Endocrine Abstracts

Introduction: Growth hormone (GH) is a lipolytic hormone with pleitropic metabolic functions. The effects of long-term GH substitution in pituitary insufficient patients with growth hormone deficiency (GHD) on lipid metabolism and bone mineralisation (BMD) have yet to be ascertained.Methods: We measured fasting total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, glucose and insulin concentrations in 52 GHD on ...

Introduction: GH substitution in GH deficiency (GHD) must be subcutaneously administered daily. Recently, a new sustained release formulation of GH (LB03002) has been developed which has to be injected only once per week. As a sub-study to the double-blind, randomized, placebo-controlled, multicenter, phase-III-study we performed this prospective study to evaluate influences of the new GH formulation on metabolic parameters and the hormones leptin and ghrelin in adult patients...

Introduction: GH rises dose dependently during treatment with the GH receptor antagonist pegvisomant. Ghrelin stimulates GH secretion. In de novo acromegalic patients with high GH levels, ghrelin levels are lowered and fat mass is reduced. Leptin levels are positively correlated to fat mass. We performed this cross-sectional study to evaluate whether elevated endogenous GH in acromegalic patients on pegvisomant treatment (peg) reduces ghrelin and leptin levels.<p class="ab...

In GH deficiency (GHD), fat mass is elevated compared to normal subjects. Leptin is positively related to fat mass, BMI and food intake, while ghrelin correlates negatively. During an oral glucose tolerance test (OGTT), leptin increases in obese subjects and generally does not change in normal weight subjects. Ghrelin decreases during OGTT. We performed a cross-sectional study in order to investigate the influence of GH-substitution on leptin and ghrelin in GHD.<p class="a...

Nadir growth hormone (GH) levels after oral glucose tolerance test (OGTT) as well as random insulin-like growth-factor I (IGF-I) levels, given as multiples of the upper limit of normal [xULN], were used to evaluate biochemical activitiy of acromegalic patients. The development of new, more sensitive GH assays makes it necessary to reevaluate the cut off values of the GH nadir after OGTT.In a cross sectional study, we evaluated nadir GH concentrations dur...

Introduction: Acromegaly is a chronic disease that affects morphology and organ functions. These changes lead to clinically relevant comorbidities. Untreated acromegaly reduces life expectancy by 10 years, mostly due to cardiovascular events, malignancies and respiratory disorders. We present the results of a series of 109 acromegalic patients at a single institution.Methods: Lung function tests were performed under standardized conditions in patients wi...

Introduction: Craniopharyngioma is an insidious disease that leads to profound comorbidities. Outcomes of the disease have been studied in depth, but there is little data comparing pituitary comorbidities of cases diagnosed in recent years opposed to before. We hypothesized that advances in endocrinologic diagnostics and neurosurgery have led to a lower degree of comorbidities.Methods: We investigated 54 patients with adult-onset craniopharyngioma (28 ma...

Introduction: SUB:Pituitary – Clinical (Generously supported by IPSEN)It is still unclear whether obesity in craniopharyngioma (CP) is caused by disorders in food regulation or by changes in mood or activity due to depression or sleepiness leading to a decrease in energy consumption. We compared CP to patients with non-functioning pituitary adenoma (NFPA) by using standardized questionnaires to clarify this question.Methods: We compared 31 ...

Introduction: Patients with craniopharyngeoma often have disturbances of the hypothalamic–pituitary axis and serious comorbidities as obesity. We hypothesized, that the pattern of hormones regulating the nutritional status is worsened in adult patients with craniopharyngioma (CP) compared to adult patients with non-functioning pituitary adenoma (NFPA).Methods: We included 33 patients with CP (m=16, f=17, median age: 48 years (26–7...

In chronic diseases patient (pat) often need continuous med treatment. In acromegaly and neuroendocrine tumors (GEP-NET), long term monthly injections of somatostatin analogues as Sandostatin® LAR® (SA®) are the treatment of choice. Problems regarding pat management and drug application might arise in not-specialized centers such as general practicioners (GP). To optimize pat’ management and compliance a homecare project* wa...